• <menu id="gwki4"><strong id="gwki4"></strong></menu>
  • <menu id="gwki4"><tt id="gwki4"></tt></menu>
    <center id="gwki4"></center>
    <xmp id="gwki4"><menu id="gwki4"></menu><menu id="gwki4"><strong id="gwki4"></strong></menu>
    <nav id="gwki4"></nav>
  • Bristol-Myers Squibb and Nektar Therapeutics Enter Global Collaboration Agreement



    ristol-Myers Squibb entered a global strategic collaboration with Nektar Therapeutics to jointly research an experimental immunotherapy across nine tumor types.?

    The collaboration agreement focuses on a CD122-biased agonist, which is an investigational immuno-stimulatory therapy designed to selectively expand cancer-fighting T cells and natural killer (NK) cells directly in the tumor microenvironment and potentially increase PD-1 expression on those immune cells.

    Under the terms of the agreement, Bristol-Myers Squibb will make an upfront cash payment of $1 billion and an equity investment of $850 million (8,284,600 shares of Nektar’s common stock at $102.60 per share). Nektar is also eligible to receive an additional $1.78 billion in milestones, of which $1.43 billion are development and regulatory milestones and the remainder are sales milestones.

    Nektar Therapeutics, based in San Francisco, is a biopharmaceutical company with a robust, wholly-owned R&D pipeline of investigational medicines in oncology, immunology and pain as well as a portfolio of approved partnered medicines.?

    To learn more about the collaboration agreement with Nektar Therapeutics, view the press release here.